Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Serichim
Torviscosa, Friuli Venezia Giulia, Italy
- Ownership
- Private
- Development stage
- Other
01
Overview
Serichim develops processes for generic APIs including ritonavir, gabapentin, and rosiglitazone using continuous manufacturing; recently concluded development of a biosimilar insulin analogue with ongoing licensing negotiations.[1][2][6]
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Partnerships
ICGEB (International Center for Genetic Engineering and Biotechnology)Bracco ImagingBMGPharma SpAUniversity of UdineUniversity of Urbino
Beyond the preview
Go deeper on Serichim.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serichim.